UK expects to save 75% from adalimumab rivals

30 Nov 2018
News

Executive Summary

Savings of around 75% on the cost of adalimumab are expected by the UK’s National Health Service (NHS) “after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug”. The NHS said it had “moved swiftly to drive strong competition between biosimilar manufacturers and the manufacturer of the originator brand, resulting in huge cost discounts”.

Already Registered? Sign in to continue reading.

New to Generics Bulletin? Request a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

GB001506

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

GB001506

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

UK expects to save 75% from adalimumab rivals

News

Executive Summary

Related Content

Fresenius Nod In EU Adds To Crowded Adalimumab Market

German Adalimumab Biosimilars Near A Third

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert